Recurrent Breast Cancer Terminated Phase 1 Trials for Trastuzumab (DB00072)

Also known as: Breast Cancer Recurrent / Breast cancer NOS recurrent / Carcinoma breast recurrent / Breast carcinoma recurrent / Breast carcinoma NOS recurrent

IndicationStatusPhase
DBCOND0028640 (Recurrent Breast Cancer)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00039455Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast CancerTreatment
NCT01705340Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By SurgeryTreatment